METX — ME Therapeutics Holdings Cashflow Statement
0.000.00%
Last trade - 00:00- CA$266.30m
- CA$264.40m
- 45
- 21
- 76
- 45
Annual cashflow statement for ME Therapeutics Holdings, fiscal year end - August 31st, CAD millions except per share, conversion factor applied.
2020 August 31st | 2021 August 31st | 2022 August 31st | 2023 August 31st | 2024 August 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | PROSPECTUS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -0.052 | -0.071 | -0.146 | -6.52 | -1.29 |
| Depreciation | |||||
| Non-Cash Items | 0.017 | 0.029 | 0.024 | 6.17 | 0.699 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 0.001 | 0.045 | -0.014 | 0.043 | -0.063 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Accounts Payable | |||||
| Change in Payable / Accrued Expenses | |||||
| Cash from Operating Activities | -0.034 | 0.003 | -0.136 | -0.303 | -0.658 |
| Other Investing Cash Flow Items | — | — | — | 0.757 | 0 |
| Sale of Business | |||||
| Cash from Investing Activities | — | — | — | 0.757 | 0 |
| Financing Cash Flow Items | — | — | — | — | -0.007 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 0.07 | 0.02 | 0.14 | 0.116 | 1.51 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 0.036 | 0.023 | 0.004 | 0.57 | 0.85 |